Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis

Conclusion
Long-term treatment with bosentan reduces the risk of developing PAH in patients with systemic sclerosis.

Source: Journal of International Medical Research - September 27, 2016 Category: Research Authors: Murdaca, G., Lantieri, F., Puppo, F., Bezante, G. P., Balbi, M. Tags: Immuno-Mediated Diseases and CV Risk Source Type: research